You just read:

CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

News provided by

CytRx Corporation

29 Nov, 2016, 07:00 ET